Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OPWV 6.70 Harbinger Allows Tender Offer for Openwave Shares to Expire
Jun 22, 2007 8:44:00 AM
NEW YORK, June 22 /PRNewswire/ -- Harbinger Capital Partners Master Fund I, Ltd. and Harbinger Capital Partners Special Situations Fund, L.P. (together, "Harbinger") announced that it has allowed its tender offer for shares of common stock of Openwave Systems Inc. ("Openwave")(Nasdaq: OPWV) to expire at the originally-scheduled expiration time of 12:00 Midnight, New York City time on Thursday, June 21, 2007 (the "Expiration Time").
As of the Expiration Time, 27,980,640 shares of Openwave common stock (including pursuant to notices of guaranteed delivery) were validly tendered in the tender offer, or approximately 40% of the shares outstanding which are not owned by Harbinger or management and directors of Openwave. This was an insufficient number of shares to meet the minimum condition set forth in Harbinger's tender offer documents. In addition, Openwave's board didn't take the necessary action to satisfy those conditions to the tender offer which were in its exclusive control. Therefore, Harbinger will not take up the shares tendered and will allow the tender offer to expire without extension. For further information please contact Taylor Rafferty at the number listed below.
IMPORTANT INFORMATION
This press release is neither an offer to purchase nor a solicitation of an offer to sell any securities. Any tender offer will be made only through an offer to purchase and related materials. In connection with the tender offer, Harbinger has filed a Tender Offer Statement on Schedule TO (containing an offer to purchase (as amended from time to time, the "Offer to Purchase"), a letter of transmittal and related materials) with the Securities and Exchange Commission on May 22, 2007. Investors and security holders of Openwave are advised to read the Schedule TO (as may be amended from time to time), the Offer to Purchase and other disclosure materials (collectively, the "Disclosure Materials"), when they are filed and become available, because these materials will contain important information. You should consider the information contained in the Disclosure Materials before making any decision about the tender offer or whether to tender your shares. Investors and security holders may obtain a free copy of the Disclosure Materials as well as any documents filed by Openwave with the Securities and Exchange Commission at the SEC's website at www.sec.gov. The Disclosure Materials may also be obtained from the information agent for the tender offer at no cost after the tender offer is commenced.
CAUTIONARY STATEMENTS
This press release contains "forward-looking statements". Forward-looking statements made in this release are subject to risks and uncertainties. Forward-looking statements include statements that are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "plans," "anticipates," "estimates," "expects", "intends", "seeks" or similar expressions. In addition, any statements we may provide concerning future financial performance, ongoing business strategies or prospects, and possible future actions, including with respect to our strategy following completion of the Offer and our plans with respect to Openwave, are also forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and are subject to risks, uncertainties and assumptions about Openwave, economic and market factors and the industry in which Openwave does business, among other things. You should not place undue reliance on forward-looking statements, which are based on current expectations, since, while Harbinger believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove accurate. This cautionary statement is applicable to all forward-looking statements contained in this press release. These statements are not guarantees of future performance. All forward-looking statements included in this press release are made as of the date hereof and, unless otherwise required by applicable law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of factors.
For further information contact:
John W. McCullough
Vice President and Associate General Counsel
Harbert Management Corporation
Telephone: (205) 987-5576
E-mail: Jmccullough@harbert.net
or
John Dooley
Taylor Rafferty
Telephone: (212) 889-4350
Email: harbinger@taylor-rafferty.com
SOURCE Harbinger Capital Partners
----------------------------------------------
John W. McCullough
Vice President and Associate General Counsel of Harbert Management Corporation
+1-205-987-5576
Jmccullough@harbert.net; or John Dooley of Taylor Rafferty
+1-212-889-4350
harbinger@taylor-rafferty.com
for Harbinger Capital Partners
PRM 2.97 PRIMEDIA Inc. Files Information Statement Relating to the Proposed Sale of Its Enthusiast Media Division
Shareholder Vote Gives Board Discretion to Implement a 1 - 6 Reverse Stock Split
Jun 22, 2007 8:31:00 AM
Copyright Business Wire 2007
NEW YORK--(BUSINESS WIRE)--
PRIMEDIA Inc. (NYSE: PRM) today filed with the U.S. Securities and Exchange Commission its preliminary information statement relating to the sale of its Enthusiast Media Division ("PEM") to Source Interlink Companies, Inc. PRIMEDIA announced on May 13, 2007 its agreement to sell PEM to Source Interlink for cash consideration of $1,177,900,000 pursuant to the Stock Purchase Agreement entered into by PRIMEDIA, Source Interlink and Consumer Source Inc. PRIMEDIA's Board of Directors and the holders of a majority of PRIMEDIA's capital stock entitled to vote on the transaction previously approved the Stock Purchase Agreement and the sale of PEM.
As disclosed in the preliminary information statement, PRIMEDIA's Board of Directors has approved a proposed amendment to the Company's Certificate of Incorporation by which PRIMEDIA may effect a 1-for-6 reverse stock split of its common stock. The holders of a majority of PRIMEDIA's capital stock entitled to vote thereon have consented to the proposed amendment. If the reverse stock split is effected, each PRIMEDIA stockholder will receive one new share of PRIMEDIA common stock in exchange for every six existing shares of PRIMEDIA common stock. PRIMEDIA's Board of Directors has sole discretion to determine whether to effect the proposed reverse stock split, which may occur before or after the closing of the proposed sale of PEM, or whether to abandon the proposed reverse stock split.
No vote or additional consent of the PRIMEDIA stockholders is required in connection with the proposed sale of PEM or the proposed reverse stock split. Additional details regarding the proposed sale of PEM and the proposed reverse stock split are set forth in the preliminary information statement. PRIMEDIA expects to file a definitive information statement with the U.S. Securities and Exchange Commission, and mail the definitive information statement to its stockholders in accordance with applicable securities laws, in early July 2007.
About PRIMEDIA
PRIMEDIA Inc. is the parent company of Consumer Source Inc., the #1 publisher and distributor of free consumer guides in the U.S. with Apartment Guide, Auto Guide, and New Home Guide, distributing free consumer publications through its proprietary distribution network, DistribuTech, in more than 60,000 locations. Consumer Source owns and operates leading websites including ApartmentGuide.com, AutoGuide.com, NewHomeGuide.com; and America's largest online single unit rental property business, comprised of RentClicks.com, RentalHouses.com, HomeRentalAds.com, and Rentals.com.
This release contains forward-looking statements as that term is used under the Private Securities Litigation Act of 1995. These forward-looking statements are based on the current assumptions, expectations and projections of the Company's management about future events. Although the assumptions, expectations and projections reflected in these forward-looking statements represent management's best judgment at the time of this release, the Company can give no assurance that they will prove to be correct. Numerous factors, including those related to market conditions and those detailed from time-to-time in the Company's filings with the Securities and Exchange Commission, may cause results of the Company to differ materially from those anticipated in these forward-looking statements. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. These forward-looking statements are subject to risks and uncertainties and, therefore, actual results may differ materially. The Company cautions you not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to "Company" and "PRIMEDIA" as used throughout this release refer to PRIMEDIA Inc. and its subsidiaries.
Source: PRIMEDIA Inc.
----------------------------------------------
PRIMEDIA Inc.
Investors:
Eric M. Leeds
212-745-1885
or
Media:
Josh Hochberg
212-446-1892
TRU 8.20 Trust Venture Company, LLC Announces Waiver of Minimum Condition of the Tender Offer for Torch Energy Royalty Trust
Jun 22, 2007 8:30:00 AM
GREENWICH, Conn., June 22 /PRNewswire-FirstCall/ -- Trust Venture Company, LLC ("Trust Venture"), which currently has underway a tender offer (the "Offer") for any and all of the outstanding Units of Beneficial Interest ("Units") of Torch Energy Royalty Trust (NYSE: TRU), today announced that it has waived the Offer's minimum tender condition. The Offer's minimum tender condition conditioned the Offer on Trust Venture receiving in the Offer valid and not withdrawn tenders for Units that, together with the Units owned by Trust Venture as of the commencement of the Offer, would constitute at least 66 2/3% of the outstanding Units (the "Minimum Condition"). As a result of Trust Venture waiving the minimum tender condition, Trust Venture will accept for payment any and all Units validly tendered and not withdrawn in the Offer upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 10, 2007, as amended and supplemented, and the related Letter of Transmittal, except that the Minimum Condition will not apply.
Unit holders who validly tender their Units and do not withdraw such Units prior to the expiration of the Offer will receive $8.25 per Unit, net to the seller in cash, without interest. The Offer will expire at 12:00 midnight, New York City time, on Thursday, June 28, 2007, unless extended.
The members of Trust Venture are Trust Acquisition Company, LLC, a Delaware limited liability company, and Douglas L. Holbrook. Trust Venture currently owns 315,600 Units, representing approximately 3.7% of the 8,600,000 Units currently outstanding.
Baker Botts L.L.P. is acting as legal counsel to Trust Venture in connection with the tender offer. Innisfree M&A Incorporated is acting as information agent and The Bank of New York is acting as depositary.
Important Legal Information
This press release is for informational purposes only and is not an offer to purchase or the solicitation of an offer to sell any Units.
THE TENDER OFFER IS BEING MADE PURSUANT TO THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED MATERIALS. UNIT HOLDERS ARE URGED TO READ TRUST VENTURE'S OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED MATERIALS, INCLUDING THE SCHEDULE TO ON MAY 10, 2007, AS AMENDED BY AMENDMENT NO. 1 ON MAY 29, 2007, AMENDMENT NO. 2 ON JUNE 8, 2007 AND AMENDMENT NO. 3 ON JUNE 22, 2007, REGARDING THE TENDER OFFER THAT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE VARIOUS TERMS OF, AND CONDITIONS TO, THE TENDER OFFER. UNIT HOLDERS MAY OBTAIN FREE COPIES OF THESE DOCUMENTS AT THE SEC'S WEB SITE AT WWW.SEC.GOV OR BY CALLING INNISFREE M&A INCORPORATED, THE INFORMATION AGENT FOR THE OFFER AT 888-750-5834 (TOLL FREE FROM THE U.S. AND CANADA). UNIT HOLDERS SHOULD NOT CONSTRUE THE CONTENTS OF THIS RELEASE OR OTHER MATERIALS FURNISHED TO THEM BY TRUST VENTURE OR ITS SERVICE PROVIDERS AS INVESTMENT, LEGAL OR TAX ADVICE. EACH UNIT HOLDER SHOULD CONSULT WITH ITS OWN PROFESSIONAL ADVISERS AS TO WHETHER TO PARTICIPATE IN THE TENDER OFFER.
Contacts:
Investors: Media:
Innisfree M&A Incorporated Kekst and Company
Alan Miller/Jennifer Shotwell Adam Weiner/Todd Fogarty
212-750-5833 212-521-4800
SOURCE Trust Venture Company, LLC
----------------------------------------------
Investors
Alan Miller or Jennifer Shotwell of Innisfree M&A Incorporated
+1-212-750-5833; or Media
Adam Weiner or Todd Fogarty of Kekst and Company
+1-212-521-4800
all for Trust Venture Company
LLC
ALXA 9.08 Alexza Selected to Join Russell 3000(R) Index
Jun 22, 2007 8:30:00 AM
PALO ALTO, Calif., June 22 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has been selected to be included in the Russell 3000(R) Index and the small-cap Russell 2000(R) Index. This inclusion will be effective at the close of trading on June 22, 2007, when the Russell Investment Group reconstitutes its family of United States Indexes. Annual reconstitution of Russell's U.S. indexes captures the 3,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. The largest 1,000 companies in this ranking comprise the Russell 1000(R) Index and the next largest 2,000 companies become the Russell 2000(R) Index. The Russell 3000(R) Index serves as the U.S. component of the Russell Global(R) Index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
About Alexza Pharmaceuticals
Alexza is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has six product candidates in development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic patients, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.
SOURCE Alexza Pharmaceuticals, Inc.
----------------------------------------------
Thomas B. King
President & CEO of Alexza Pharmaceuticals
Inc.
+1-650-687-3900
tking@alexza.com
PILL 1.98 MedAvant Announces Expanded Financing Agreement
Jun 22, 2007 8:30:00 AM
2007 PrimeNewswire, Inc.
ATLANTA, June 22, 2007 (PRIME NEWSWIRE) -- MedAvant Healthcare Solutions (MedAvant) (Nasdaq:PILL), a leader in healthcare technology and transaction services, today announced it has signed an expanded financing agreement with Laurus Master Fund, LTD, providing an additional $4.2 million of availability under its existing agreement.
"This financing immediately strengthens our financial position and provides us with the capital to leverage our technology by offering new services such as our recently announced front-end solutions for insurance payers," said John Lettko, MedAvant president and CEO.
Details on the terms of the agreement are available in MedAvant's 8-K, filed with the Securities and Exchange Commission.
About MedAvant Healthcare Solutions
MedAvant provides information technology used to process transactions within the healthcare industry. MedAvant offers electronic claims processing to healthcare providers, a Preferred Provider Organization called the National Preferred Provider Network (NPPN)(tm) and remote reporting solutions for medical laboratories. To facilitate these services, MedAvant operates Phoenix(sm), a highly scalable platform which supports real-time connections between healthcare clients. For more information, visit http://www.medavanthealth.com. MedAvant is a trade name of ProxyMed, Inc.
The MedAvant Healthcare Solutions logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3540
Forward Looking Statement
Statements in this release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. Actual results could differ materially from projected results because of factors such as: the soundness of our business strategies relative to the perceived market opportunities; MedAvant's ability to successfully develop, market, sell, cross-sell, install and upgrade its clinical and financial transaction services and applications to current and new physicians, payers, medical laboratories and pharmacies; the ability to compete effectively on price and support services; MedAvant's ability and that of its business associates to perform satisfactorily under the terms of its contractual obligations, and to comply with various government rules regarding healthcare and patient privacy; entry into markets with vigorous competition, market acceptance of existing products and services, changes in licensing programs, product price discounts, delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels; the availability of competitive products or services; the continued ability to protect the company's intellectual property rights, implementation of operating cost structures that align with revenue growth; uninsured losses; adverse results in legal disputes resulting in liabilities; unanticipated tax liabilities; the effects of a natural disaster or other catastrophic event beyond our control that results in the destruction or disruption of any of our critical business or information technology systems. Any of these factors could cause the actual results to differ materially from the guidance given at this time. For further cautions about the risks of investing in MedAvant, we refer you to the documents MedAvant files from time to time with the Securities and Exchange Commission, including, without limitation, its most recently filed Annual Report on Form 10-K. MedAvant does not assume, and expressly disclaims, any obligation to update information contained in this document. Although this release may remain available on our website or elsewhere, its continued availability does not indicate that we are reaffirming or confirming any of the information contained herein.
CONTACT: MedAvant Healthcare Solutions
Sarah Zimmerman
404-368-2598
szimmerman@medavanthealth.com
Institutional Marketing Services, Inc.
Investor Relations
John G. Nesbett
203-972-9200
jnesbett@institutionalms.com
STEI 8.34 Stewart Enterprises Prices $250 Million Senior Convertible Note Offering
Jun 22, 2007 8:30:00 AM
Copyright Business Wire 2007
NEW ORLEANS--(BUSINESS WIRE)--
Stewart Enterprises, Inc. (Nasdaq GS: STEI) today announced the pricing of $125 million principal amount of senior convertible notes due 2014 and $125 million principal amount of senior convertible notes due 2016. The notes are being offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Interest will be payable on the 2014 notes semiannually at a rate of 3.125 percent per year, and on the 2016 notes semiannually at a rate of 3.375 percent per year. The initial conversion rate for the 2014 notes and 2016 notes is 90.4936 shares of Class A common stock per $1,000 principal amount of the notes, which is equal to a conversion price of approximately $11.05 per share. The conversion price represents a premium of 32.5% based on the closing price of the Company's Class A common stock of $8.34 per share on June 21, 2007. The 2014 notes will mature on July 15, 2014 and the 2016 notes will mature on July 15, 2016. The notes are guaranteed by substantially all of the subsidiaries that guarantee the Company's 6.25% senior notes due 2013.
The notes will be convertible under specified circumstances. Upon conversion, holders will receive cash up to the principal amount, and any excess conversion value will be delivered, at the Company's election, in cash, Class A common stock or a combination of cash and Class A common stock.
Stewart has purchased call options from an affiliate of one of the initial purchasers of the notes for approximately $60.0 million. The call options will offset Stewart's exposure to dilution from conversion of the notes because any shares Stewart would be obligated to deliver to noteholders upon conversion of the notes would be delivered to Stewart by the counterparty to the call options. Stewart has also sold to the counterparty to the call options, for approximately $43.8 million, warrants expiring in 2014 and 2016 to purchase 11.3 million and 11.3 million shares of Class A common stock, respectively. The strike prices of the warrants expiring in 2014 and 2016 are $12.93 per share of Class A common stock and $13.76 per share of Class A common stock, respectively, which are 55% and 65%, respectively, higher than the closing price of the Company's Class A common stock on June 21, 2007.
Stewart intends to use approximately $164.0 million of the net proceeds of the offering to prepay the remaining balance of its Term Loan B, including accrued interest, and approximately $16.2 million of the net proceeds to pay the net cost of the call options and warrants. The Company intends to use approximately $64.2 million of the net proceeds to repurchase, concurrently with the offering, shares of its Class A common stock in negotiated transactions. The remainder of any of the net proceeds will be used for general corporate purposes.
In connection with the call options and warrants, the affiliate of the initial purchaser that will be a party to those transactions has advised the Company that it expects to enter into various derivative transactions with respect to the Company's Class A common stock and/or purchase the Company's Class A common stock in secondary market transactions concurrently with or shortly after the pricing of the notes, and may enter into or unwind various derivative transactions with respect to the Company's Class A common stock and/or purchase or sell the Company's Class A common stock in secondary market transactions following pricing of the notes.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. Any offers of securities will be made only by means of a private offering memorandum.
The 2014 and 2016 notes and shares of Class A common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.
Founded in 1910, Stewart Enterprises is the second largest provider of products and services in the death care industry in the United States. The Company currently owns and operates 226 funeral homes and 142 cemeteries in the United States and Puerto Rico. Through its subsidiaries, the Company provides a complete range of funeral merchandise and services, along with cemetery property, merchandise and services, both at the time of need and on a preneed basis.
The matters discussed in this release include forward-looking statements. These statements are based on current expectations or beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including without limitation, whether or not the Company will consummate the offering, the call option transactions or the warrant transactions, which depends, among other things, on market conditions and the satisfaction of closing conditions. For a detailed discussion of other cautionary statements relating to the Company, please refer to the Company's most recent filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this news release and assumes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release.
Source: Stewart Enterprises, Inc.
----------------------------------------------
Stewart Enterprises
Inc.
Thomas M. Kitchen
504-729-1400
KERX 10.12 Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
Jun 22, 2007 8:29:00 AM
NEW YORK, June 22 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstracts related to Sulonex(TM) (sulodexide oral gelcap) have been selected for publication or presentation during the poster sessions scheduled to take place at the upcoming American Diabetes Association (ADA) 67th Annual Scientific Sessions and exposition at the McCormick Place Lakeside Center in Chicago, Illinois.
Copies of these abstracts, which highlight the mechanism of action of Sulonex(TM) as well as observed clinical activity, are currently available and can be viewed on-line through the ADA website: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Locator.DisplaySea rchAbstract&CalledByID=1006
Abstracts selected for poster presentation include the following:
Saturday, June 23, 2007 (12:30pm-2:30pm):
0733 - Role of Reactive Oxygen Species in High Glucose-Induced Heparanase
Expression and Heparan Sulfate Proteoglycan Degradation in the Human
Endothelial Cells XIULONG XU, GEETHA RAO, WENDY HUANG, RICHARD A. PRINZ,
EDMUND J. LEWIS, Chicago, IL
Sunday, June 24, 2007 (6:15pm-7:30pm):
0573 - Treatment of Diabetic Nephropathy with Sulodexide: Final Phase II
Safety and Efficacy Results EDMUND J. LEWIS, JULIA LEWIS, SAMUEL S.
BLUMENTHAL, THOMAS WIEGMANN, LAWRENCE HUNISCKER, ITAMAR RAZ, Chicago, IL,
Nashville, TN, Milwaukee, WI, Kansas City, KS, Iowa City, IA, Jerusalem,
Israel
0769 - Mechanism and Relevance of Reduced Presence of Glomerular Heparan
Sulfate for Proteinuria in Overt Diabetic Nephropathy TESSA WIJNHOVEN,
MABEL VAN DEN HOVEN, TOIN H. VAN KUPPEVELT, JOHAN VAN DER VLAG, JO H.
BERDEN, RICHARD A. PRINZ, EDMUND J. LEWIS, MELVIN SCHWARTZ, XIULONG XU,
Nijmegen, Netherlands Antilles, Chicago, IL
Additional abstracts of interest include:
2220 - Oral Administration of Sulodexide for the Treatment of Diabetic
Nephropathy in a Phase II Study has Minimal to No Effect on Coagulation or
Fibrinolytic Activity JULIA LEWIS, ITAMAR RAZ, SHERWYN SCHWARTZ, STEPHEN
ARONOFF, MURRAY KATZ, GILBERT EISNER, JAMES MERSEY, Nashville, TN,
Jerusalem, Israel, San Antonio, TX, Dallas, TX, Tucson, AZ, Washington,
DC, Baltimore, MD
2376 - Efficacy and Safety of Sulodexide in the Treatment of Diabetic
Nephropathy RAM WEISS, ROBERT M. NIECESTRO, ITAMAR RAZ, Jerusalem, Israel,
New York, NY
ABOUT SULONEX(TM)
Sulonex (sulodexide oral gelcap) belongs to a proposed new class of nephroprotective, or kidney protecting, drugs, known as the glycosaminoglycans. A variety of members of this chemical family have been shown to decrease pathological albumin excretion in diabetic nephropathy in humans. Some of the members of this chemical family include the following approved drugs: standard heparin, low molecular weight heparin and danaparoid. These agents all require therapy by injection and are all potent anticoagulants, which are blood thinners capable of inducing bleeding. Sulonex, on the other hand, is given orally and, in this form, has demonstrated little, if any, anticoagulant effects to date.
Keryx owns the exclusive rights to use Sulonex(TM) for the treatment of diabetic nephropathy in North America, Japan and certain other markets outside of Europe. Diabetic nephropathy is a long-term complication of diabetes in which the kidneys are progressively damaged. Sulonex is a glycosaminoglycan compound with structural similarities to the broad family of marketed heparins and low molecular weight heparins. This drug has been marketed in a number of European, Asian and South American countries for many years by our licensor for certain cardiovascular conditions and has an established safety profile at the doses used for such indications. Additionally, it has been demonstrated in multiple clinical trials conducted in Europe and the U.S., including two randomized, double-blind, placebo-controlled Phase II studies, that Sulonex can reduce urinary protein excretion in patients with diabetic nephropathy. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment, or SPA, with the Food & Drug Administration, or FDA. These trials are being conducted by the Collaborative Study Group, or the CSG, the world's largest standing renal clinical trials group.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT: Ronald C. Renaud Jr.
Chief Financial Officer, Treasurer
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
SOURCE Keryx Biopharmaceuticals, Inc.
----------------------------------------------
Ronald C. Renaud Jr.
Chief Financial Officer
Treasurer of Keryx Biopharmaceuticals
Inc.
+1-212-531-5965
BSM 6.75 Twelve-Year Survival Data Shows Durability of Hyperthermia Therapy's Enhancement of Radiation in Treating Cancer
Jun 22, 2007 8:05:00 AM
SALT LAKE CITY, June 22 /PRNewswire-FirstCall/ -- BSD Medical Corp. (Amex: BSM) announced today that a report delivered at the European Society for Hyperthermic Oncology (ESHO) conference recently held in Prague revealed the 12-year follow-up survival data for advanced cervical cancer patients treated with radiation plus hyperthermia therapy, as compared to radiation treatments alone. The original study was a Phase III clinical trial involving 358 patients with locally advanced pelvic tumors conducted at the University Hospital of Daniel den Hoed Cancer Center in Rotterdam and the Academic Medical Center in Amsterdam. The 114 cervical cancer patients enrolled in the study had tumors that were advanced, and their prognosis was generally grave.
In April 2000 the LANCET (a highly-regarded London-based medical journal) published the 3-year survival follow-up data for advanced cervical cancer patients in the study, showing a 51% survival rate for patients who received radiation plus hyperthermia therapy, as opposed to 27% of those who received radiation therapy alone (see LANCET vol. 355, pp. 1119-1125). According to the recent report at the ESHO conference, after 12 years the survival rate for the patients who received radiation plus hyperthermia therapy was 37%, as compared to a survival rate of 20% for patients who received radiation alone (p=0.03).
One of the primary concerns about the viability of new therapies is their durability. According to this study, the margin of increased survival rate was reported to be approximately the same at 12 years (an 85% increase) as it was at 3 years (an 89% increase) for patients who received hyperthermia therapy in addition to radiation treatments.
The lead author in this study was Jacoba van der Zee, M. D. Funding for the study was provided by the Dutch Health Insurance Council.
This study involved the use of the BSD-2000 by BSD Medical Corp. for delivery of precision-focused hyperthermia therapy. BSD Medical Corp. is a leading developer of systems used to provide therapies involving precision-focused heat for the treatment of cancer. For further information visit BSD Medical's website at http://www.BSDMedical.com or BSD's patient website at http://www.treatwithheat.com.
Statements contained in this press release that are not historical facts are forward-looking statements, including future prospects for the company relating to research described herein, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE BSD Medical Corp.
----------------------------------------------
Hyrum A. Mead
+1-801-972-5555
fax
+1-801-972-5930
investor@bsdmc.com
for BSD Medical Corp.
CDE 3.68 Coeur d'Alene and Bolnisi Extend Due Diligence Period
Jun 22, 2007 8:00:00 AM
COEUR D'ALENE, Idaho, June 22 /PRNewswire-FirstCall/ -- Coeur d'Alene Mines Corporation (NYSE: CDE; TSX: CDM) today announced that Bolnisi has agreed to extend Coeur's due diligence period to July 3, 2007, under the Merger Implementation Agreement relating to Coeur's proposed acquisition of Bolnisi, which is part of a larger transaction that also would result in Coeur's acquisition of Palmarejo Silver and Gold Corporation (TSX-V: PJO).
As previously announced on June 8, 2007, Coeur and Bolnisi agreed to extend Coeur's due diligence period by 14 days to June 22, 2007.
About Coeur d'Alene
Coeur d'Alene Mines Corporation is one of the world's leading primary silver producers and a growing gold producer. The company has mining interests in Alaska, Argentina, Australia, Bolivia, Chile, Nevada, and Tanzania.
Cautionary Statement --
This press release contains forward-looking statements within the meaning of securities legislation in the United States and Canada, including statements regarding a possible transaction and anticipated operating results. Such statements are subject to numerous assumptions and uncertainties, many of which are outside Coeur's control. Operating, exploration and other statements in this press release are based on information that Coeur believes is reasonable, but involve significant uncertainties affecting the business of Coeur, including, but not limited to, future gold and silver prices, costs, ore grades, estimation of gold and silver reserves, mining and processing conditions, construction schedules, currency exchange rates, and the completion and/or updating of mining feasibility studies, changes that could result from future acquisitions of new mining properties or businesses, the risks and hazards inherent in the mining business (including environmental hazards, industrial accidents, weather or geologically related conditions), regulatory and permitting matters, risks inherent in the ownership and operation of, or investment in, mining properties or businesses in foreign countries, as well as other uncertainties and risk factors set out in filings made from time to time with the SEC and the Ontario Securities Commission, including, without limitation, Coeur's reports on Form 10-K and Form 10-Q. As disclosed in this press release, there are risks that the parties will not proceed with the transaction, that the ultimate terms of the transaction will differ from those that currently are contemplated, and that the results, developments and timetables could vary significantly from the estimates presented. Readers are cautioned not to put undue reliance on forward-looking statements. Coeur disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, Coeur undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of Coeur, its financial or operating results or its securities or the possible transaction.
Additional Information -
The proxy statement that Coeur plans to file with the United States Securities and Exchange Commission ("SEC") and Ontario Securities Commission and mail to its shareholders will contain information about Coeur, Bolnisi, Palmarejo, the Palmarejo Project, the transaction and related matters. Shareholders are urged to read the proxy statement carefully when it is available, as it will contain important information that shareholders should consider before making a decision about the transaction. In addition to receiving the proxy statement from Coeur by mail, shareholders will also be able to obtain the proxy statement, as well as other filings containing information about Coeur, without charge, from the SEC's website (www.sec.gov) and the Canadian securities regulators' website (www.sedar.com) or, without charge, from Coeur. This announcement is neither a solicitation of a proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Coeur. Coeur and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Coeur's shareholders with respect to the proposed transaction. Information regarding any interests that Coeur's executive officers and directors may have in the transaction will be set forth in the proxy statement. The Coeur shares to be issued in the transaction have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Coeur intends to issue such Coeur shares pursuant to the exemption from registration set forth in Section 3(a)(10) of the Securities Act.
Copies of the merger implementation agreements and certain related documents will be filed with the SEC and Canadian securities regulators and will be available at the SEC's website at www.sec.gov and at the Canadian securities regulators' website at www.sedar.com.
Contacts
Coeur
Mitchell J. Krebs
Senior Vice President - Corporate Development
(888) 545-1138
Tony Ebersole
Director of Investor Relations
(208) 665-0777
Matthew Sherman / Jennifer Schaefer
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
SOURCE Coeur d'Alene Mines Corporation
----------------------------------------------
Mitchell J. Krebs
Senior Vice President - Corporate Development
+1-888-545-1138
Tony Ebersole
Director of Investor Relations
+1-208-665-0777
both of Coeur; Matthew Sherman or Jennifer Schaefer
both of Joele Frank
Wilkinson Brimmer Katcher
+1-212-355-4449
for Coeur
KOG 5.85 Kodiak Oil & Gas Updates Operations
Jun 22, 2007 8:00:00 AM
DENVER, June 22 /PRNewswire-FirstCall/ -- Kodiak Oil & Gas Corp. (Amex: KOG) an oil and gas exploration and production company with assets in the Green River and Williston Basins, today provided an update on its North Trail Federal #4-35 well in the Vermillion Basin in Wyoming.
Vermillion Basin - Wyoming
The Company announces that it has reached total depth on its NT Fed #4-35 well (Kodiak 100% WI) of 13,655 feet and has run a pre-perforated production string to a total depth of 13,655 feet. The Company reports that the well encountered gas shows in several fractures that were intercepted by the 1,655 feet of horizontal lateral of the main target within the Baxter shale. Due to mechanical difficulties created by the gas encountered, and the subsequent increase in the weight of the drilling mud required to control the gas flow, the well did not reach its projected horizontal length of 2,700 feet. Completion efforts will follow immediately.
In an effort to minimize damage to the reservoir, completion efforts will be staged. Initially, the pre-perforated liner will not be cemented into the horizontal leg of the well. Furthermore, the well will not be mechanically stimulated, but rather will be turned to sales to evaluate the production potential from the natural fractures that are open in the well bore. By monitoring the production data from the well, a process common in early-stage plays, Kodiak engineers hope to gain additional information about reservoir quality and characteristics. The length of this testing period will be determined based upon the production rates achieved, and could last from a few weeks to a few months.
The Company has elected to defer fracture stimulation until a later date, which typically leads to lower initial production rates than if fracture stimulated immediately. Once the production rates through natural fractures have been evaluated, the well will then be mechanically stimulated through modern hydraulic fracture procedures. With current natural gas price differentials afflicting Rockies producers, management believes it is an opportune time to move methodically on the well to try and gain additional knowledge of the reservoir to best recover the hydrocarbons in place.
Kodiak has built location for the HB #5-3 well located on the western edge of the prospective producing area. As this well will be the first well drilled in the township to the prospective horizon, the well will be drilled vertically to a depth of 13,800 feet to evaluate the potential of the Mesaverde formations, the Baxter shale and the Frontier sandstone. Subject to drilling results from the vertical well bore, the well could then be drilled horizontally within the Baxter shale. Kodiak will serve as operator and will have an approximate 60% working interest in the well, with Devon Energy as its drilling partner.
The Company has completed permitting procedures on an approximate 43- square-mile 3-D seismic program on the northern block of its acreage which includes portions of its Chicken Springs and Chicken Ranch Federal Units, as well as land currently not included in federal units. Data acquisition should begin in mid-July with processing and interpretation completed late 3rd quarter.
Lynn Peterson, Kodiak's CEO and President said: "We are encouraged by the amount of gas and the natural fracturing that we have encountered while drilling the NT Fed #4-35. We are obviously in the over-pressured environment that we anticipated. Kodiak is in the early days of what could be a significant Rockies exploration play, and with such exploration comes a learning curve that we and other operators throughout the Rockies are experiencing. It is our belief that the amount of gas in place here is meaningful, as evidenced in part by the gas shows encountered with each well. We will take the opportunity to carefully analyze the well so that we may apply the knowledge gleaned when drilling future wells."
About Kodiak Oil & Gas Corp.
Kodiak Oil & Gas, headquartered in Denver, is an independent energy exploration and development company focused on exploring, developing and producing oil and natural gas in the Williston and Green River Basins in the U.S. Rocky Mountains. For further information, please visit www.kodiakog.com. The common shares of the Company are listed for trading on the American Stock Exchange under the symbol "KOG."
Forward-Looking Statements
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," 'projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Information inferred from the interpretation of drilling results may also be deemed to be forward-looking statements, as it constitutes a prediction of what might be found to be present when and if a well is actually developed. Forward-looking statements in this document include statements regarding the Company's exploration, drilling and development plans, the Company's expectations regarding the timing and success of such programs and the Company's expectations regarding the future production of its oil & gas properties. Factors that could cause or contribute to such differences include, but are not limited to, fluctuations in the prices of oil and gas, uncertainties inherent in estimating quantities of oil and gas reserves and projecting future rates of production and timing of development activities, competition, operating risks, acquisition risks, liquidity and capital requirements, the effects of governmental regulation, adverse changes in the market for the Company's oil and gas production, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission.
SOURCE Kodiak Oil & Gas Corp.
----------------------------------------------
Mr. Lynn A. Peterson
President of Kodiak Oil & Gas Corp.
+1-303-592-8075; or Mr. David Charles of EnerCom
Inc.
+1-303-296-8834
for Kodiak Oil & Gas Corp.
ACTI 4.58 ActivIdentity to Demonstrate Smart Employee ID Solution at the 2007 North American Burton Group Catalyst Conference
Jun 22, 2007 8:00:00 AM
WHAT: ActivIdentity Corporation (Nasdaq: ACTI), a global leader in
digital identity assurance, will be demonstrating its Smart
Employee ID, the all in one smart card for building, workstation,
and network access, at the 2007 North American Burton Group
Catalyst Conference. The company will also be hosting a
hospitality suite at the event. Catalyst is designed to bring IT
leaders together to learn about and discuss today's most
significant technology topics and complex issues faced by
enterprise organizations.
WHERE: The conference will take place at the Hilton San Francisco, located
at 333 O'Farrell Street, San Francisco, CA 94102. The
ActivIdentity hospitality suite will be located in the hotel's
Franciscan Room A.
WHEN: ActivIdentity will demonstrate its Smart Employee ID on June 27,
2007 from 6:00 p.m. to 9:30 p.m., Pacific Daylight Time (PDT). For
more information on the conference please visit
http://catalyst.burtongroup.com/NA07/index.html.
About ActivIdentity
ActivIdentity Corporation (Nasdaq: ACTI) is the trusted provider of identity assurance solutions for the enterprise, government, healthcare, and financial services markets worldwide. The company provides the only fully- integrated platform enabling organizations to issue, manage and use identity devices and credentials for secure access, secure communications, legally binding digital transactions, as well as smart citizen services.
ActivIdentity customers experience multiple benefits including increased network security, protection against identity theft and online fraud, enhanced workforce productivity, business process efficiencies, and regulatory compliance.
ActivIdentity solutions include Smart Employee ID, Enterprise Single Sign On, Strong Authentication, Secure Information and Transactions, and Smart Citizen ID.
More than 15 million users and 4,000 customers worldwide rely on solutions from ActivIdentity. Headquartered in Fremont, Calif., the company has development centers in the United States, Australia, France, and sales and service centers in more than ten countries. For more information, visit httpP://www.actividentity.com.
ActivIdentity and ActivCard are registered trademarks in the United States and/or other countries. All other trademarks are the property of their respective owners in the United States and/or other countries.
Media Contact:
Timothy Polakowski
McGrath/Power Public Relations
408.727.0351
timothyp@mcgrathpower.com
(Logo: http://www.newscom.com/cgi-bin/prnh/20051108/SFTU161LOGO)
SOURCE ActivIdentity Corporation
DCGN 4.10 Families of Spinal Muscular Atrophy Announces Major Breakthrough in Development of Drug Candidate for Currently Untreatable Disease
The First Novel Clinical Candidate for Spinal Muscular Atrophy is Selected
Jun 22, 2007 8:00:00 AM
LIBERTYVILLE, Ill., June 22 /PRNewswire/ -- Families of Spinal Muscular Atrophy (FSMA) is pleased to announce the selection of a Clinical Candidate for Spinal Muscular Atrophy through its program being conducted at deCODE chemistry. At the same time FSMA is now extending its contract with deCODE to continue work towards an Investigational New Drug (IND) application with the Food and Drug Administration. If successful, this would be the first novel drug designed specifically to treat Spinal Muscular Atrophy (SMA).
SMA is a genetic disorder with no current treatment that is the leading killer of children under two years of age. SMA is typically marked by the degeneration of voluntary muscle movement including the muscles that control crawling, walking, swallowing or breathing. This is an important step in the development of a small molecule therapeutic for this debilitating and normally fatal disease.
The lead compounds have shown the ability to extend survival in a mouse model of SMA. Due to this successful result the organizations have now been able to select a Clinical Candidate. This is the first time a novel compound specifically designed to treat SMA has reached this stage in drug development. Families of SMA has been funding and directing this particular program for the last 7 years. The total investment to date in this program alone is over $10M.
"Selecting a Clinical Candidate means that we are now preparing to run the safety tests required to apply to the FDA to begin clinical trials. This work will require funding of $2.5M and take almost 12 months to complete," said Kenneth Hobby, Executive Director of Families of SMA. "If we are successful in this stage we would then look to start phase I clinical trials."
"Excitingly, the program has identified drug-like compounds that act on SMA patient cells in culture to increase SMN2 gene activity and thereby the amount of functional SMN protein. The same compounds also have therapeutic benefit in a mouse model of a severe form of SMA. We are very pleased to see the project come this far," said Mark Gurney, Senior Vice President, deCODE genetics and deCODE chemistry.
"To our knowledge this is the first novel program for SMA that has reached this stage," said Dr. Jill Jarecki, FSMA Research Director. "The goal of the deCODE collaboration was to generate a final optimized compound with the required properties of an effective SMA drug, called a "Clinical Candidate". Now in May of 2007 this goal has been met. As will be reported at the upcoming FSMA-sponsored 11th Annual International SMA Group Meeting in June, our compounds prolong survival in mouse models of SMA and are very effective at crossing the blood brain barrier to reach motor neurons in the spinal cord. We are very optimistic about the potential of moving this drug to IND within the next year, and the lessons we are learning will help strengthen the SMA drug pipeline."
About Families of Spinal Muscular Atrophy
FSMA is dedicated to eradicating SMA by promoting and supporting research, helping families cope through informational programs and support, and educating the public and the medical community about SMA. The organization, originally founded in 1984 by a small group of parents, has grown to more than 32 chapters and affiliates worldwide and more than 5,000 member families. FSMA receives the majority of its funding through volunteer efforts, funding over $30 million to date, and continues to increase its funding commitments each year with $15 million in new research planned over the next three years. In addition, Families of SMA has funded more than $3 million in patient support efforts.
Since its founding, FSMA-sponsored research has made significant contributions to better understanding SMA and advancing new therapies towards human clinical testing. These accomplishments include:
-- Identification of a mutation in the SMN1 gene as the cause of the
disease. A second copy of the gene called SMN2 produces reduced amounts
of SMN protein due to a defect in splicing.
-- The funding of two leading-edge drug discovery programs designed to
increase functional protein production from the SMN2 gene to compensate
for the loss of the SMN1 gene.
-- The establishment of Project CURE SMA, a 7 center clinical trial
network, which is currently testing two medications for their possible
impact on treating SMA patients. This network will also serve as the
conduit for future human drug trials.
For more information about FSMA visit the website http://www.curesma.org
or call 1-800-886-1762.
About deCODE chemistry, Inc.
deCODE chemistry, Inc. is a wholly-owned subsidiary of deCODE genetics (Nasdaq: DCGN) providing research services to world-class pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. deCODE chemistry, along with deCODE biostructures, conducts collaborative drug discovery and development for pharmaceutical and biotechnology companies using an integrated platform of structural biology and chemistry technologies. Our services are designed to help our clients develop small molecule therapeutics with the greatest promise of efficacy, selectivity, and safety in the clinic.
SOURCE Families of Spinal Muscular Atrophy
----------------------------------------------
Lenna Scott of Families of Spinal Muscular Atrophy
+1-847-975-4171
BITI 7.00 Bio-Imaging Technologies to Join Russell Microcap Index
Jun 22, 2007 8:00:00 AM
Copyright Business Wire 2007
NEWTOWN, Pa.--(BUSINESS WIRE)--
Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced that it will join the Russell Microcap(TM) Index when the Russell Investment Group reconstitutes its family of US indices on June 22, according to a preliminary list of additions posted on www.russell.com.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indices. Russell determines membership for its equity indices primarily by objective, market-capitalization rankings and style attributes.
Mark L. Weinstein, President and Chief Executive Officer of Bio-Imaging, said, "Inclusion in the Russell Microcap Index underscores our solid financial position and a growing recognition of Bio-Imaging by the investment community. We look forward to the increased visibility provided by our inclusion in the Russell Microcap Index and are grateful for the continued support of our investors and their confidence in our management team."
About Russell
Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors. For more information on Russell indices, go to www.russell.com.
Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands and its recent acquisition of Theralys SA in Lyon, France. Through its CapMed division, Bio-Imaging provides the Personal HealthKey(TM) technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.
Source: Bio-Imaging Technologies, Inc.
----------------------------------------------
Bio-Imaging Technologies
Inc.
Mark L. Weinstein
President & CEO
Ted I. Kaminer
CFO
267-757-3000
IR@bioimaging.com
or
Porter
LeVay & Rose
Inc.
Linda Decker
VP - Investor Relations
212-564-4700
or
Tom Gibson
VP - Media Relations
201-476-0322
NSHV .042/.051
HOKU..congrats!!! :)
it looks like these days pinks are more solid plays than even low float OTCBB plays....i see so many of those things pop n drop!
IVGR can't do squat on 15 x avg vol and AVVW most recent. IHGR is iffy as well right now.
FPLF .0003/.0005 1x1
NSHV .048x2 .053x1 (1 min chart says up time is here)
IVGR .0016/.0018
FMDA .69 Futuremedia Regains Compliance With Nasdaq Listing Requirements
Jun 21, 2007 2:18:00 PM
BRIGHTON, England, June 21 /PRNewswire-FirstCall/ -- Futuremedia plc (Nasdaq: FMDA), a leading learning and brand communications provider, today announced it received a Nasdaq Staff Letter, dated June 20, 2007, advising that the Company has regained compliance with Marketplace Rule 4350 (the "Rule"), which requires a Company's audit committee to be composed of at least three independent directors.
The Directors of Futuremedia plc formally reconstituted the Company's audit committee and remuneration committee on June 18, 2007. The Company's four independent directors are all on both committees, as follows: Margot Lebenberg, Brendan McNutt (Chairman of the Audit Committee), Michiel Steel (Chairman of the Remuneration Committee), and Jan Vandamme.
As previously announced on May 23, 2007, Futuremedia had received a Nasdaq Staff Deficiency letter, indicating that the Company was not in compliance with the requirement that the audit committee be composed of at least three independent directors. On June 4, 2007 the Company announced the appointment of George O'Leary, Margot Lebenberg and Brendan McNutt as Directors of the Company. The Company subsequently reconstituted the Company's audit committee and remuneration committee on June 18, 2007 and the Company has therefore regained compliance with the Nasdaq Marketplace Rules.
"Safe Harbor" Statement under Section 21E of the Securities Exchange Act of 1934: This press release contains forward-looking statements related to future results and speaks only of Futuremedia's expectations as of the date hereof. Such statements include expectations regarding: the Company's ability to maintain its listing on the Nasdaq-CM; the expected benefits from new sales, contracts or products; the expected benefits and success of operations in new markets; the expected benefits of expanding the sales operations of group companies into new geographical markets; the expected benefits of acquisitions; the expected benefits of financing arrangements; and the Company's future financial condition and performance. Such statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from expectations. The risks and uncertainties include: risks associated with the Company's ability to maintain its listing on the Nasdaq C-M; risks associated with the Company's ability to develop and successfully market new services and products (including the risk that such products may not be accepted in the market), risks relating to operations in new markets (including the risk that such operations may not deliver anticipated revenue or profits); risks associated with acquisitions (including the risk that such acquisitions may not deliver the benefits expected by management and risks associated with integration of acquisitions generally); risks that financing arrangements could result in substantial dilution to shareholders because of subscription prices below the current market value of the Company's ADSs or other factors; risks relating to the Company's ability to operate profitably in the future; risks associated with rapid growth; the Company's ability to successfully develop its business in new geographic markets; the early stage of the e-learning market; rapid technological change and competition; and other factors detailed in the Company's filings with the US Securities and Exchange Commission. The Company expressly disclaims any obligation to release publicly any updates or revisions to any such statement to reflect any change in expectations or in information on which any such statement is based. All product names and trademarks mentioned herein are trademarks of Futuremedia or their respective owners.
About Futuremedia
Futuremedia plc is a global media company providing online education, e-marketing and brand communications services to public and private sector organizations. Established in 1982 and listed on the Nasdaq in 1993, we help our clients to communicate their values, product and brand information to employees, customers and industry, and we believe that education, or learning, is a key component in the communication mix. Futuremedia divisions are Futuremedia Learning and Button Communications. For more information, visit www.futuremedia.co.uk
SOURCE Futuremedia plc
----------------------------------------------
US - Mike Smargiassi
or Dianne Pascarella
+1-212-986-6667
ir@futuremedia.co.uk
both of Brainerd Communicators
Inc.; UK - Gerry Buckland
+44-7919-564126
infomac1@mac.com
all for Futuremedia
FMDA .69 Futuremedia Regains Compliance With Nasdaq Listing Requirements
Jun 21, 2007 2:18:00 PM
BRIGHTON, England, June 21 /PRNewswire-FirstCall/ -- Futuremedia plc (Nasdaq: FMDA), a leading learning and brand communications provider, today announced it received a Nasdaq Staff Letter, dated June 20, 2007, advising that the Company has regained compliance with Marketplace Rule 4350 (the "Rule"), which requires a Company's audit committee to be composed of at least three independent directors.
The Directors of Futuremedia plc formally reconstituted the Company's audit committee and remuneration committee on June 18, 2007. The Company's four independent directors are all on both committees, as follows: Margot Lebenberg, Brendan McNutt (Chairman of the Audit Committee), Michiel Steel (Chairman of the Remuneration Committee), and Jan Vandamme.
As previously announced on May 23, 2007, Futuremedia had received a Nasdaq Staff Deficiency letter, indicating that the Company was not in compliance with the requirement that the audit committee be composed of at least three independent directors. On June 4, 2007 the Company announced the appointment of George O'Leary, Margot Lebenberg and Brendan McNutt as Directors of the Company. The Company subsequently reconstituted the Company's audit committee and remuneration committee on June 18, 2007 and the Company has therefore regained compliance with the Nasdaq Marketplace Rules.
"Safe Harbor" Statement under Section 21E of the Securities Exchange Act of 1934: This press release contains forward-looking statements related to future results and speaks only of Futuremedia's expectations as of the date hereof. Such statements include expectations regarding: the Company's ability to maintain its listing on the Nasdaq-CM; the expected benefits from new sales, contracts or products; the expected benefits and success of operations in new markets; the expected benefits of expanding the sales operations of group companies into new geographical markets; the expected benefits of acquisitions; the expected benefits of financing arrangements; and the Company's future financial condition and performance. Such statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from expectations. The risks and uncertainties include: risks associated with the Company's ability to maintain its listing on the Nasdaq C-M; risks associated with the Company's ability to develop and successfully market new services and products (including the risk that such products may not be accepted in the market), risks relating to operations in new markets (including the risk that such operations may not deliver anticipated revenue or profits); risks associated with acquisitions (including the risk that such acquisitions may not deliver the benefits expected by management and risks associated with integration of acquisitions generally); risks that financing arrangements could result in substantial dilution to shareholders because of subscription prices below the current market value of the Company's ADSs or other factors; risks relating to the Company's ability to operate profitably in the future; risks associated with rapid growth; the Company's ability to successfully develop its business in new geographic markets; the early stage of the e-learning market; rapid technological change and competition; and other factors detailed in the Company's filings with the US Securities and Exchange Commission. The Company expressly disclaims any obligation to release publicly any updates or revisions to any such statement to reflect any change in expectations or in information on which any such statement is based. All product names and trademarks mentioned herein are trademarks of Futuremedia or their respective owners.
About Futuremedia
Futuremedia plc is a global media company providing online education, e-marketing and brand communications services to public and private sector organizations. Established in 1982 and listed on the Nasdaq in 1993, we help our clients to communicate their values, product and brand information to employees, customers and industry, and we believe that education, or learning, is a key component in the communication mix. Futuremedia divisions are Futuremedia Learning and Button Communications. For more information, visit www.futuremedia.co.uk
SOURCE Futuremedia plc
----------------------------------------------
US - Mike Smargiassi
or Dianne Pascarella
+1-212-986-6667
ir@futuremedia.co.uk
both of Brainerd Communicators
Inc.; UK - Gerry Buckland
+44-7919-564126
infomac1@mac.com
all for Futuremedia
IVGR .0014/.0015 2x1>>edit .0015/.0018 1x2
welcome!
cool! AVVW
6/22/2007 HGCP 1-20 R/S ** Hansen Gray & Company, Inc. New Common Stock ACPI AMF Capital, Inc. Common Stock
6/22/2007 HGCP 1-20 R/S ** Hansen Gray & Company, Inc. New Common Stock ACPI AMF Capital, Inc. Common Stock
6/22/2007 HGCP 1-20 R/S ** Hansen Gray & Company, Inc. New Common Stock ACPI AMF Capital, Inc. Common Stock
:) INSANE! ivgr .0014/.0015 2X2
IVGR .0014/.0015
IHGR .0028/.0029 1X1
NSHV .049/.053 1x1
IHGR ut .0031/.0035...they fill trades at ask and then drop itto .0027/.0029
u got that right!
VFIN on ask
IVGR .0014/.0015 1x2...it should be moving up with that confirmed 97M OS...hmmm
IVGR .0013x2 .0015x2
GLLK L2
NSHV .048/.053 1x1
ty! it is so true.
NSHV .049/.053 1x1